



10 September 2020

AIM: RENE

ReNeuron Group plc
("ReNeuron" or the "Company")

Result of AGM

ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, announces that all resolutions put to shareholders at its Annual General Meeting ("AGM") held earlier today were duly passed.

The details of proxy voting are being made available in the investor section of the Company's website, <http://www.reneuron.com/investors/general-meeting/>.

Following completion of the AGM, the Company has entered into a relationship agreement with Obotritia Capital KGaA, as indicated in the Company's announcement of 12 August 2020, to ensure that the Company is capable of carrying on its business independently at all times.

ENDS

ENQUIRIES:

ReNeuron Olav Hellebø , Chief Executive Officer Michael Hunt, Chief Financial Officer	+44 (0) 20 3819 8400
Buchanan (Media/Investor relations) Mark Court, Tilly Abraham	+44 (0) 20 7466 5000
Stifel Nicolaus Europe Limited (NOMAD and Joint Broker) Ben Maddison, Stewart Wallace	+44 (0) 20 7710 7600
N+1 Singer (Joint Broker) Aubrey Powell, James Moat, Tom Salvesen	+44 (0) 20 7496 3000

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa, and for disability as a result of stroke.

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain. The Company also has the ability

through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com.